Stryker Corporation
NYSE:SYKMedical - Devices
+$9.29 today
- Market cap
- $121.12B
- Beta
- 0.79
- P/E (TTM)
- 35.6
- EPS (TTM)
- $8.72
- Dividend yield
- 1.11%
Volume 3.25M
Average 2.49M
SYK EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Stryker CorporationNYSE: SYK
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) growth accelerates
Q2 FY2026 EPS (Diluted) of $3.3 rose 44.1% year over year, ahead of the +27.8% change in trailing-twelve-month EPS (Diluted). Sequentially, it rose 71.0% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.
Context
- EPS (Diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 16 analysts of $14.84 (+76.6%) for the fiscal year ending Dec 2026, a step up from the +8.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.3+71.0% QoQ
- Last fiscal yearDec 2025
- $8.4+8.2% YoY
- LTMJun 2026
- $9.65+27.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +44.1% | +59.8% | +15.7 pp |
| 1 year | +8.2% | +76.6% | +68.4 pp |
| 3-year CAGR | +10.8% | +29.1% | +18.3 pp |
| 5-year CAGR | +20.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 8.40 USD
- Year-over-year change
- +8.2%
- 4-year CAGR
- +12.6%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.40 | +8.2% |
| FY2024 | 2024-12-31 | 7.76 | -5.9% |
| FY2023 | 2023-12-31 | 8.25 | +33.7% |
| FY2022 | 2022-12-31 | 6.17 | +18.2% |
| FY2021 | 2021-12-31 | 5.22 | — |
EPS (Diluted) vs competitors
How SYK compares with its peers on the latest reported figures
- SYK's LTM Jun 2026 EPS (Diluted) of $9.65 is the highest of the 11 companies compared; the peer median is $0.73.
- Its year-over-year change of +27.8% is the 6th highest of 11, against a peer median of +19.8%.
- Over three fiscal years its annual growth of +10.8% compares with a peer median of +35.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $9.65 | +27.8% | +10.8% | |
| LTM Jun 2026 | $4.11 | +0.0% | +47.8% | |
| LTM Jul 2026 | $4.06 | +11.8% | +9.8% | |
| LTM Jun 2026 | $3.89 | +49.6% | +28.4% | |
| LTM Mar 2026 | $1.77 | -53.4% | — | |
| FY2025 | $1.44 | +53.2% | +42.3% | |
| LTM Mar 2026 | $0.01 | +114.1% | — | |
| LTM Mar 2026 | -$0.83 | +27.8% | — | |
| LTM Mar 2026 | -$1.51 | +59.2% | — | |
| LTM Mar 2026 | -$6.48 | -1605.9% | — | |
| LTM Apr 2026 | -$20.02 | -43.5% | — | |
| Peer median (excluding SYK) | $0.73 | +19.8% | +35.4% | |
Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.11B | 18.45B | 20.5B | 22.6B | 25.12B |
| Cost of Revenue | 6.4B | 7.41B | 8B | 8.05B | 9.05B |
| Gross Profit | 10.71B | 11.04B | 12.49B | 14.55B | 16.07B |
| Gross Margin | 62.6% | 59.8% | 61.0% | 64.4% | 64.0% |
| Research & Development | 1.13B | 1.23B | 1.29B | 1.47B | 1.58B |
| Selling, General & Admin | 5.81B | 6.08B | 6.92B | 7.5B | 8.65B |
| Operating Expenses | 6.95B | 7.31B | 8.21B | 10.86B | 11.18B |
| Depreciation & Amortization | 990M | 998M | 1.03B | 1.05B | 1.19B |
| EBITDA | 3.61B | 4.02B | 5.06B | 6.01B | 6.31B |
| EBITDA Margin | 21.1% | 21.8% | 24.7% | 26.6% | 25.1% |
| Operating Income | 3.76B | 3.73B | 4.28B | 3.69B | 4.89B |
| Operating Margin | 22.0% | 20.2% | 20.9% | 16.3% | 19.5% |
| Interest Income | 68M | 94M | 75M | 139M | 121M |
| Interest Expense | 337M | 337M | 356M | 396M | 607M |
| Other Income / Expenses | (1.48B) | (1.05B) | (608M) | (197M) | (375M) |
| Income Before Tax | 2.28B | 2.68B | 3.67B | 3.49B | 4.51B |
| Pre-Tax Margin | 13.3% | 14.5% | 17.9% | 15.5% | 18.0% |
| Income Tax Expense | 287M | 325M | 508M | 499M | 1.27B |
| Net Income | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Net Margin | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
| EPS (Basic) | 5.29 | 6.23 | 8.34 | 7.86 | 8.49 |
| EPS (Diluted) | 5.22 | 6.17 | 8.25 | 7.76 | 8.40 |
| Weighted Avg Shares | 377M | 378.2M | 379.6M | 381M | 382.2M |
| Weighted Avg Shares (Diluted) | 382.3M | 382.2M | 383.7M | 385.6M | 382.2M |
Stryker Corporation
NYSE:SYK
Intrinsic Alpha fair value
Locked
Current Price
$318.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.